Multiple sclerosis (MS) is a common neurological disorder characterized by inflammation and plaque formation in the white matter of the brain. It is generally considered to have an autoimmune component influenced by both genetic and environmental factors. We have investigated the ubiquitous human herpes virus 6 (HHV-6) and its possible role in the etiology and immunopathology of MS. The immune response against HHV-6 is different in MS patients compared to controls. MS patients have increased levels of anti-HHV-6 IgM in serum and CSF, 1 indicating a re-infection, a persistent infection or a reactivation of the virus. They also have higher lymphoproliferative responses and a higher T cell precursor frequency against the A variant of HHV-6, 2 suggesting an active virus-specific immune response. In addition to these virus-specific humoral and cellular immune responses we detect viral DNA in serum, urine and plaques from MS patients. 3 Previous studies have suggested that the presence of serum HHV-6 DNA is reflective of active replication of the virus. 4 These data support an association between HHV-6 infection and MS. Whether or not the virus is a causative agent of this disease still remains to be proven.
Multiple sclerosis is the most prevalent demyelinating disease in humans, affecting over 350 000 Americans. The clinical neurological symptoms are consistent with damage to the white matter tracts within the central nervous system (CNS). The course of the disease can vary from the most common relapsing-remitting form to primary progressive cases. Neuropathologically the hallmark of this disease is plaque formation in the CNS. The presence of myelin reactive T and B cells at the site of inflammation in the brain suggests that autoimmune mechanisms are involved in the pathogenesis of the disease. 5 While there are clear genetic influences associated with MS, environmental factors have also been suggested to play a role. For many years, an infectious etiology of MS has been suspected as it fits with a number of epidemiological observations. These include: (1) 11, 12 and (5) analogy with animal models and other human diseases in which viruses can cause diseases with a relapsing remitting course and demyelination after long incubation periods. However, no virus to date has been definitively shown to be the sole agent that is the 'cause' of MS. After many years of intensive research the etiology of this disorder is still unknown.
Most recently, the possible association between the newly described human herpesvirus 6 (HHV-6) and MS has gained considerable attention. This association was first suggested by Sola et al 13 and confirmed by Challoner and colleagues in 1995, when they identified HHV-6 in MS brains using an unbiased screening method termed representational differential analysis (RDA). 14 The presence of HHV-6 DNA was found in over 70% of both MS patients brains and controls, but HHV-6 protein expression was only identified in plaques and non-plaques of MS brains.
More than 90% of the adult population are seropositive for HHV-6 (for review see Braun 1997) . 15 There are two strains, termed A and B, with 75-95% similarities depending on the genes compared. The HHV-6B variant is the etiological agent of the common childhood disease roseola infantum also known as exanthem subitum (ES), but to date, no disease has been uniquely associated with an HHV-6A primary infection. Like the other herpesviruses, HHV-6 is a common opportunistic pathogen, with active replication detected in immunosuppressed patients.
How then does one demonstrate an association with a ubiquitous viral agent (HHV-6) and disease such as MS? Our laboratory has extensively studied another chronic, progressive neurological disease known to be associated with the human T lymphotropic retrovirus type I (HTLV-I). 16 The disease is termed HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP) and is clinically indistinguishable from the primary progressive form of MS. Importantly, while over 10-20 million people worldwide are infected with HTLV-I, only a small percentage (Ͻ5%) develop neurological disease. The question we address is how a virus that affects so many people, can be associated with disease in only a subset of infected individuals. Many of the approaches that have been used to study HTLV-I associated neurological disease can also be used to analyze the relationship between HHV-6 and MS. In general, a multi-dimensional approach has been taken in which immunological, molecular, and pathological observations have been made to suggest that HHV-6 may play a role in the pathogenesis of MS.
We first investigated the seroprevalence of anti-HHV-6 antibodies in MS patients and controls and found that the HHV-6 specific IgM titers were significantly elevated in MS patients (P = 0.011), whereas there was no difference in the HHV-6 specific IgG titer. 1 This could indicate that MS patients are more prone to react to any viral infections, but since we did not detect an increase in IgM response against EBV or CMV in the same patients, specificity against HHV-6 is suggested. Several other studies have confirmed these results, though a few have not (Table 1 ). These discrepancies are undoubtedly due to different assay systems used to detect either IgG or IgM and highlight the need for uniformity in assay design and reagent availability.
We confirmed the serological results with lymphoproliferative studies and analysis of T cell precursors. While most healthy controls (71%) and MS patients (78%) responded to the HHV-6B variant, lymphocytes from a significantly higher percentage of the MS patients proliferated to the HHV-6A variant (67%) compared with the controls (33%). No difference was observed to the lymphoproliferative response to HHV-7 between MS patients and controls. 2 When T cell precursor frequencies were analyzed, MS patients were demonstrated to have a significant increase in the frequency of HHV-6A specific T cells in peripheral blood, whereas the precursor frequencies against the B variant and HHV-7 were similar to controls (Soldan SS, manuscript in preparation).
Detection of viral DNA in body fluids has been used as a marker of active infection. 4 We investigated PBL, saliva, serum and urine from MS patients and controls with a sensitive nested PCR method. There was a predominant detection of HHV-6A DNA sequences in cellfree compartments, such as serum and urine, which was not detected from serum and urine of controls. In contrast, there was no difference in the detection of HHV-6B DNA sequences in PBL and saliva of MS patients and controls. The detection of HHV-6 DNA in cell-associated material is consistent with lifelong persistence of HHV-6, particularly HHV-6B which is acquired in childhood. The observation that HHV-6A DNA could be detected in cell-free fluids suggest that there is an active HHV-6 infection ongoing in MS patients more often than can be detected in healthy controls, other inflammatory diseases and other neurological diseases. This implies either a disability of the immune system to handle a ubiquitous infection or a reactivation of a latent infection. The higher neurotropism of the HHV-6A variant makes these results even more intriguing with regard to the role that HHV-6A may play in the pathogenesis of MS. However, depending on the prevalence of HHV-6A, which is still unknown, a higher exposure to this variant in MS patients might also be considered.
The aforementioned results were based on studies from which samples were taken from MS patients and controls at single points in time. However, most MS patients have a relapsing/remitting disease course characterized by distinct periods of clinical exacerbations. It was therefore of interest to determine if evidence of HHV-6 could be obtained that correlated with MS disease progression. In a limited study, 58 MS patients were followed over a period of 6 months from whom blood samples were obtained from at least two time points. HHV-6 serum DNA was statistically more likely to be demonstrated from serum obtained during a clinical exacerbation than from a period of remission (Berti et al, manuscript in preparation). This might suggest that re-infection or reactivation of a latent HHV-6 infection may be associated with these exacerbations. It is always difficult to determine whether the virus 'causes' symptoms or the detection of this agent is an 'effect' of other events associated with the patients' clinical activity. For example, the stress of an exacerbation might induce a reactivation of the virus or make the patient more sensitive to infection.
To support further the role of HHV-6 in MS, neuropathological assessment of autopsy MS brain tissue was analyzed for the presence of HHV-6 DNA. Small pieces of brain material from MS plaques and nonplaques were laser microdisected, and HHV-6 DNA was extracted and amplified by nested-PCR (Cermelli C, manuscript submitted). HHV-6 DNA was detected more frequently in MS lesions compared to non-lesions (normal appearing white matter, NAWM) in MS brains. Moreover, the frequency of HHV-6 DNA in non-MS and normal brains was similar to NAWM. In addition, HHV-6 RNA was also detected more often in the plaques than in non-plaques of MS brains, suggesting that the virus was replicating at the MS lesion site. HHV-6 RNA was also demonstrated in a small number of NAWM areas. These observations are in concordance with the original findings of Challoner's and the new in situ PCR work by Blumberg 17 and suggest that activity of the virus may precede plaque formation.
There are several ways in which a virus could be associated with inflammation in the brain. The simplest explanation is that clinical symptoms are a result of the normal immune response against a neurotropic virus. The plaque formation in the brain might then be a result of the appropriate immunological clearing of virus-infected cells. Another possibility is that viruses are capable of altering the immune system, which could lead to increased inflammation in the brain and a disregulation of the immune response. Ubiquitous viruses, like the herpesviruses, have evolved several mechanisms to avoid detection and elimination by the immune system, including blocking of antigen presentation and regulation of cytokine expression. 18 With immuno microarray technology we have identified several genes of the immune system that are induced and reduced by the HHV-6 in vitro. A number of proinflammatory genes were shown to be up-regulated by HHV-6. These RNA expression studies have been verified by measuring cytokines by ELISA. Differences in which genes were up or down regulated were also observed between the HHV-6A and B variant (Mayne M, manuscript in preparation).
MS is a multifactorial disease, influenced by several genes and environmental factors. Over the years a number of viruses have been reported to be associated with MS, though none of the associations has stood the test of time and proved to be a definitive causative agent. Detailed neuropathology of the MS brain has suggested a complex disorder consistent with the concept that MS may be a heterogeneous disease both in its presentation and progression. 19 In a sense, this could imply that multiple mechanisms can give the same outcome in different individuals and that a viral etiology might only explain a subset of the MS cases. Of this subset there might be several different viruses that can cause the same disease symptoms through similar mechanisms. A common factor shared by HHV-6 and measles virus, another ubiquitous virus previously reported to be associated with MS, is the cellular receptor they use, CD46. CD46, also known as membrane cofactor protein, protects the cell against complement lysis and is expressed in almost all human cells. In measuring the soluble CD46 in serum from MS patients and controls, we found a significantly higher level in
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MS patients' serum and CSF (Soldan S, manuscript accepted). Others have reported a higher level of anti-CD46 antibodies in MS patients. 20 One interpretation of these data is that CD46 is incorporated into the virion, as has been described for CMV, HIV and SIV, 21, 22 and that an anti-CD46 B cell response is generated as described for CMV and CD13. 23 In conclusion, immunological and molecular data support an association between MS and HHV-6. Virus activity can also be correlated to worsening of disease course and to the site of inflammation. However, given the multifactorial nature of the disease, a viral association might not be seen in all MS cases. Conversely, like HTLV-1 and HAM/TSP, the disease might not be seen in all individuals infected with the virus. The host genetics are undoubtedly associated with disease susceptibility. There are numerous host genes that could potentially play a role in shifting the immune response from healthy protection against a viral infection to immune-mediated destruction of the brain. Our data supporting a role of the A variant of HHV-6 in MS also indicates that specific viral genes may play significant roles in disease pathogenesis. Understanding the interaction between the immune system and ubiquitous viral infections, especially at classically considered immuno privileged sites like the brain, might give new important clues to the etiology and pathology of MS. 
